Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

References

• Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W, Chen Q. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China. Sci Rep. 2020;10(1):9104.
   PubMed Web of Science ®Google Scholar
• Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–1823.
   PubMed Web of Science ®Google Scholar
• Han D, Li X, Cheng Y. Transcription factor ELF1 modulates cisplatin sensitivity in prostate cancer by targeting MEIS homeobox 2. Chem Res Toxicol. 2023;36(3):360–368.
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015;4(3):365–380.
   PubMed Web of Science ®Google Scholar
• Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.
   PubMed Web of Science ®Google Scholar
• Chia CSB. Novel PSMA-targeting radionuclide peptidomimetics for treating prostate cancer. ACS Med Chem Lett. 2023;14(1):3–4.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023;160:114392.
   PubMed Web of Science ®Google Scholar
• Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, De Marzo AM, Nelson PS, Yegnasubramanian S. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92.
   PubMed Web of Science ®Google Scholar
• He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13(1):37–50.
   PubMed Web of Science ®Google Scholar
• Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20(7):509–530.
   PubMed Web of Science ®Google Scholar
• Shishkova E, Zeng H, Liu F, Kwiecien NW, Hebert AS, Coon JJ, Xu W. Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition. Nat Commun. 2017;8:15571.
   PubMed Web of Science ®Google Scholar
• Al-Hamashi AA, Diaz K, Huang R. Non-histone arginine methylation by protein arginine methyltransferases. Curr Protein Pept Sci. 2020;21(7):699–712.
   PubMed Web of Science ®Google Scholar
• Jacques SL, Aquino KP, Gureasko J, Boriack-Sjodin PA, Porter Scott M, Copeland RA, Riera TV. CARM1 preferentially methylates H3R17 over H3R26 through a random kinetic mechanism. Biochemistry. 2016;55(11):1635–1644.
   PubMed Web of Science ®Google Scholar
• Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, et al. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun. 2018;9(1):631.
   PubMedGoogle Scholar
• Pang L, Tian H, Chang N, Yi J, Xue L, Jiang B, Gorospe M, Zhang X, Wang W. Loss of CARM1 is linked to reduced HuR function in replicative senescence. BMC Mol Biol. 2013;14:15.
   PubMed Web of Science ®Google Scholar
• Lee YH, Bedford MT, Stallcup MR. Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation. Genes Dev. 2011;25(2):176–188.
   PubMed Web of Science ®Google Scholar
• Suresh S, Huard S, Dubois T. CARM1/PRMT4: Making its mark beyond its function as a transcriptional coactivator. Trends Cell Biol. 2021;31(5):402–417.
   PubMed Web of Science ®Google Scholar
• Kuhn P, Chumanov R, Wang Y, Ge Y, Burgess RR, Xu W. Automethylation of CARM1 allows coupling of transcription and mRNA splicing. Nucleic Acids Res. 2011;39(7):2717–2726.
   PubMed Web of Science ®Google Scholar
• Yu YS, Shin HR, Kim D, Baek SA, Choi SA, Ahn H, Shamim A, Kim J, Kim IS, Kim KK, et al. Pontin arginine methylation by CARM1 is crucial for epigenetic regulation of autophagy. Nat Commun. 2020;11(1):6297.
   PubMed Web of Science ®Google Scholar
• Grypari IM, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, Melachrinou M, Logothetis C, Tzelepi V. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine. 2021;100(36):e27094.
   PubMed Web of Science ®Google Scholar
• Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, Jung C. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer. 2010;10:197.
   PubMed Web of Science ®Google Scholar
• Wang YP, Zhou W, Wang J, Huang X, Zuo Y, Wang TS, Gao X, Xu YY, Zou SW, Liu YB, et al. Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol Cell. 2016;64(4):673–687.
   PubMed Web of Science ®Google Scholar
• Cai XC, Zhang T, Kim EJ, Jiang M, Wang K, Wang J, Chen S, Zhang N, Wu H, Li F, et al. A chemical probe of CARM1 alters epigenetic plasticity against breast cancer cell invasion. Elife. 2019;8:e47110.
   PubMed Web of Science ®Google Scholar
• Wu D, He J, Zhang W, Wang K, Jin S, Li J, Gao W. CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression. Aging. 2020;12(11):10578–10593.
   PubMedGoogle Scholar
• Ferreira de Freitas R, Eram MS, Smil D, Szewczyk MM, Kennedy S, Brown PJ, Santhakumar V, Barsyte-Lovejoy D, Arrowsmith CH, Vedadi M, et al. Discovery of a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) inhibitor by virtual screening. J Med Chem. 2016;59(14):6838–6847.
   PubMed Web of Science ®Google Scholar
• Shen Y, Szewczyk MM, Eram MS, Smil D, Kaniskan H, de Freitas RF, Senisterra G, Li F, Schapira M, Brown PJ, et al. Discovery of a potent, selective, and cell-active dual inhibitor of protein arginine methyltransferase 4 and protein arginine methyltransferase 6. J Med Chem. 2016;59(19):9124–9139.
   PubMed Web of Science ®Google Scholar
• Eram MS, Shen Y, Szewczyk M, Wu H, Senisterra G, Li F, Butler KV, Kaniskan H, Speed BA, Dela Seña C, et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem Biol. 2016;11(3):772–781.
   PubMed Web of Science ®Google Scholar
• Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, et al. Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma. Sci Rep. 2017;7(1):17993.
   PubMedGoogle Scholar
• Nakayama K, Szewczyk MM, Dela Sena C, Wu H, Dong A, Zeng H, Li F, de Freitas RF, Eram MS, Schapira M, et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma. Oncotarget. 2018;9(26):18480–18493.
   PubMedGoogle Scholar
• Li X, Zhang L, Xu J, Liu C, Zhang X, Abdelmoneim AA, Zhang Q, Ke J, Zhang Y, Wang L, et al. Identification, synthesis, and biological evaluations of potent inhibitors targeting type I protein arginine methyltransferases. J Chem Inf Model. 2022;62(3):692–702.
   PubMed Web of Science ®Google Scholar
• Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
   PubMed Web of Science ®Google Scholar
• Zhang R, Erler J, Langowski J. Histone acetylation regulates chromatin accessibility: Role of H4K16 in Inter-nucleosome interaction. Biophys J. 2017;112(3):450–459.
   PubMed Web of Science ®Google Scholar
• Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem. 2014;62(1):11–33.
   PubMed Web of Science ®Google Scholar
• Gediya P, Parikh PK, Vyas VK, Ghate MD. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders. Eur J Med Chem. 2021;216:113332.
   PubMed Web of Science ®Google Scholar
• Darvishi N, Rahimi K, Mansouri K, Fathi F, Menbari MN, Mohammadi G, Abdi M. MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression. Mol Cell Probes. 2020;53:101649.
   PubMed Web of Science ®Google Scholar
• Hulsurkar M, Li Z, Zhang Y, Li X, Zheng D, Li W. Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1. Oncogene. 2017;36(11):1525–1536.
   PubMed Web of Science ®Google Scholar
• Sirous H, Campiani G, Brogi S, Calderone V, Chemi G. Computer-driven development of an in silico tool for finding selective histone deacetylase 1 inhibitors. Molecules. 2020;25(8):1952.
   PubMed Web of Science ®Google Scholar
• Jo H, Shim K, Kim HU, Jung HS, Jeoung D. HDAC2 as a target for developing anti-cancer drugs. Comput Struct Biotechnol J. 2023;21:2048–2057.
   PubMed Web of Science ®Google Scholar
• Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87(12):4577–4597.
   PubMed Web of Science ®Google Scholar
• Chang L, Ruiz P, Ito T, Sellers WR. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell. 2021;39(4):466–479.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015;75(6):695–704.
   PubMed Web of Science ®Google Scholar
• McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.
   PubMed Web of Science ®Google Scholar
• Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 2020;11:578011.
   PubMed Web of Science ®Google Scholar
• Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, et al. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021;39(3):812–820.
   PubMed Web of Science ®Google Scholar
• Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy. J Med Chem. 2020;63(17):8977–9002.
   PubMed Web of Science ®Google Scholar
• Parray A, Siddique HR, Nanda S, Konety BR, Saleem M. Castration-resistant prostate cancer: potential targets and therapies. Biologics. 2012;6:267–276.
   PubMedGoogle Scholar
• Zhang Z, Guo Z, Xu X, Cao D, Yang H, Li Y, Shi Q, Du Z, Guo X, Wang X, et al. Structure-based discovery of potent CARM1 inhibitors for solid tumor and cancer immunology therapy. J Med Chem. 2021;64(22):16650–16674.
   PubMed Web of Science ®Google Scholar
• Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874–7887.
   PubMed Web of Science ®Google Scholar
• Ren Y, Li S, Zhu R, Wan C, Song D, Zhu J, Cai G, Long S, Kong L, Yu W. Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer. J Med Chem. 2021;64(11):7468–7482.
   PubMed Web of Science ®Google Scholar
• Wan G, Feng Z, Zhang Q, Li X, Ran K, Feng H, Luo T, Zhou S, Su C, Wei W, et al. Design and synthesis of fibroblast growth factor receptor (FGFR) and histone deacetylase (HDAC) dual inhibitors for the treatment of cancer. J Med Chem. 2022;65(24):16541–16569.
   PubMed Web of Science ®Google Scholar
• Maia EHB, Assis LC, de Oliveira TA, da Silva AM, Taranto AG. Structure-based virtual screening: from classical to artificial intelligence. Front Chem. 2020;8:343.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhong A, Wang Q, Zheng T. Structure-based pharmacophore modeling, virtual screening, molecular aocking, ADMET, and molecular dynamics (MD) simulation of potential inhibitors of PD-L1 from the library of marine natural products. Mar Drugs. 2021;20(1):29.
   PubMed Web of Science ®Google Scholar
• Kumar V, Krishna S, Siddiqi MI. Virtual screening strategies: recent advances in the identification and design of anti-cancer agents. Methods. 2015;71:64–70.
   PubMed Web of Science ®Google Scholar
• Yan F, Liu G, Chen T, Fu X, Niu MM. Structure-based virtual screening and biological evaluation of peptide inhibitors for Polo-Box domain. Molecules. 2019;25(1):107.
   PubMed Web of Science ®Google Scholar
• Wan H, Huynh T, Pang S, Geng J, Vaccaro W, Poss MA, Trainor GL, Lorenzi MV, Gottardis M, Jayaraman L, et al. Benzo[d]imidazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)–Hit to lead studies. Bioorg Med Chem Lett. 2009;19(17):5063–5066.
   PubMed Web of Science ®Google Scholar
• Hu C, Guo T, Zou Y, Gao J, Gao Y, Niu M, Xia Y, Shen X, Li J. Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies. J Enzyme Inhib Med Chem. 2023;38(1):2212327.
   PubMed Web of Science ®Google Scholar
• Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. J Med Chem. 2014;57(8):3324–3341.
   PubMed Web of Science ®Google Scholar
• Zheng L, Ren R, Sun X, Zou Y, Shi Y, Di B, Niu MM. Discovery of a dual tubulin and poly(ADP-ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation. J Med Chem. 2021;64(21):15702–15715.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yan F, Huo X, Niu MM. Discovery of a potent PLK1-PBD small-molecule inhibitor as an anticancer drug candidate through structure-based design. Molecules. 2019;24(23):4351.
   PubMed Web of Science ®Google Scholar